Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford ...

Germany’s Boehringer Ingelheim has selected a third drug candidate to move forward into IND-enabling studies under its ongoing collaboration with Oxford BioTherapeutics.

Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a new push to educate people with bronchiectasis about how to better manage the disease.

TOKYO -- German drugmaker Boehringer Ingelheim plans to invest a total of 300 million euros ($346 million) in its plant in Japan from 2023 to 2028 as it moves to make the facility a production base ...

Boehringer Ingelheim’s Spevigo (spesolimab) has been recommended by the National Institute for Health and Care Excellence ...

The site was created by Boehringer Ingelheim after a survey identified knowledge gaps among owners on many health topics ...

What happens when data projects forget the people who use them? A Disconnect. Boehringer Ingelheim turned things around by ...